SOTERA HEALTH CO (SHC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SHC • US83601L1026

17.75 USD
+0.35 (+2.01%)
At close: Feb 6, 2026
17.8 USD
+0.05 (+0.28%)
After Hours: 2/6/2026, 8:06:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, SHC scores 5 out of 10 in our fundamental rating. SHC was compared to 58 industry peers in the Life Sciences Tools & Services industry. SHC scores excellent on profitability, but there are concerns on its financial health. SHC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year SHC was profitable.
  • SHC had a positive operating cash flow in the past year.
  • In multiple years SHC reported negative net income over the last 5 years.
  • SHC had a positive operating cash flow in 4 of the past 5 years.
SHC Yearly Net Income VS EBIT VS OCF VS FCFSHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.74%, SHC is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
  • SHC has a better Return On Equity (10.07%) than 80.70% of its industry peers.
  • SHC has a Return On Invested Capital of 9.23%. This is amongst the best in the industry. SHC outperforms 82.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SHC is significantly below the industry average of 13.34%.
  • The last Return On Invested Capital (9.23%) for SHC is above the 3 year average (8.04%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.74%
ROE 10.07%
ROIC 9.23%
ROA(3y)-1.47%
ROA(5y)-0.34%
ROE(3y)-14.75%
ROE(5y)-6.62%
ROIC(3y)8.04%
ROIC(5y)7.61%
SHC Yearly ROA, ROE, ROICSHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.82%, SHC is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
  • SHC's Profit Margin has declined in the last couple of years.
  • SHC's Operating Margin of 29.89% is amongst the best of the industry. SHC outperforms 100.00% of its industry peers.
  • SHC's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 55.98%, SHC is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
  • SHC's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 29.89%
PM (TTM) 4.82%
GM 55.98%
OM growth 3Y-0.64%
OM growth 5Y2.13%
PM growth 3Y-31.23%
PM growth 5YN/A
GM growth 3Y-0.57%
GM growth 5Y1.5%
SHC Yearly Profit, Operating, Gross MarginsSHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SHC is destroying value.
  • Compared to 1 year ago, SHC has more shares outstanding
  • The number of shares outstanding for SHC has been increased compared to 5 years ago.
  • Compared to 1 year ago, SHC has a worse debt to assets ratio.
SHC Yearly Shares OutstandingSHC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
SHC Yearly Total Debt VS Total AssetsSHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • SHC has an Altman-Z score of 1.74. This is a bad value and indicates that SHC is not financially healthy and even has some risk of bankruptcy.
  • SHC has a Altman-Z score (1.74) which is comparable to the rest of the industry.
  • SHC has a debt to FCF ratio of 25.87. This is a negative value and a sign of low solvency as SHC would need 25.87 years to pay back of all of its debts.
  • SHC has a Debt to FCF ratio (25.87) which is comparable to the rest of the industry.
  • SHC has a Debt/Equity ratio of 4.04. This is a high value indicating a heavy dependency on external financing.
  • SHC has a worse Debt to Equity ratio (4.04) than 91.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.04
Debt/FCF 25.87
Altman-Z 1.74
ROIC/WACC0.83
WACC11.12%
SHC Yearly LT Debt VS Equity VS FCFSHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • SHC has a Current Ratio of 2.38. This indicates that SHC is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SHC (2.38) is comparable to the rest of the industry.
  • A Quick Ratio of 2.16 indicates that SHC has no problem at all paying its short term obligations.
  • SHC has a Quick ratio (2.16) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.16
SHC Yearly Current Assets VS Current LiabilitesSHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 8.00% over the past year.
  • The Earnings Per Share has been decreasing by -7.34% on average over the past years.
  • The Revenue for SHC has decreased by -15.95% in the past year. This is quite bad
  • Measured over the past years, SHC shows a small growth in Revenue. The Revenue has been growing by 7.17% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-7.34%
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)-15.95%
Revenue growth 3Y5.71%
Revenue growth 5Y7.17%
Sales Q2Q%9.05%

3.2 Future

  • Based on estimates for the next years, SHC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.65% on average per year.
  • The Revenue is expected to grow by 6.85% on average over the next years.
EPS Next Y20.93%
EPS Next 2Y16.36%
EPS Next 3Y14.51%
EPS Next 5Y15.65%
Revenue Next Year5.31%
Revenue Next 2Y5.6%
Revenue Next 3Y5.78%
Revenue Next 5Y6.85%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SHC Yearly Revenue VS EstimatesSHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
SHC Yearly EPS VS EstimatesSHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 21.91, SHC is valued on the expensive side.
  • Based on the Price/Earnings ratio, SHC is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
  • SHC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.93.
  • The Price/Forward Earnings ratio is 18.73, which indicates a rather expensive current valuation of SHC.
  • Based on the Price/Forward Earnings ratio, SHC is valued cheaper than 85.96% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.77, SHC is valued a bit cheaper.
Industry RankSector Rank
PE 21.91
Fwd PE 18.73
SHC Price Earnings VS Forward Price EarningsSHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • SHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SHC is cheaper than 89.47% of the companies in the same industry.
  • 61.40% of the companies in the same industry are more expensive than SHC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 58.22
EV/EBITDA 14.3
SHC Per share dataSHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • SHC's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of SHC may justify a higher PE ratio.
  • A more expensive valuation may be justified as SHC's earnings are expected to grow with 14.51% in the coming years.
PEG (NY)1.05
PEG (5Y)N/A
EPS Next 2Y16.36%
EPS Next 3Y14.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SHC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOTERA HEALTH CO

NASDAQ:SHC (2/6/2026, 8:06:02 PM)

After market: 17.8 +0.05 (+0.28%)

17.75

+0.35 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04
Earnings (Next)03-03
Inst Owners58.12%
Inst Owner Change1.61%
Ins Owners2.34%
Ins Owner Change-14.04%
Market Cap5.04B
Revenue(TTM)1.15B
Net Income(TTM)55.42M
Analysts82.86
Price Target20.85 (17.46%)
Short Float %3.14%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.17%
Min EPS beat(2)14.56%
Max EPS beat(2)17.78%
EPS beat(4)4
Avg EPS beat(4)12.29%
Min EPS beat(4)3.1%
Max EPS beat(4)17.78%
EPS beat(8)6
Avg EPS beat(8)7.28%
EPS beat(12)9
Avg EPS beat(12)7.47%
EPS beat(16)13
Avg EPS beat(16)7.3%
Revenue beat(2)2
Avg Revenue beat(2)3.57%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.63%
Revenue beat(4)3
Avg Revenue beat(4)2.11%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)0.06%
Revenue beat(12)7
Avg Revenue beat(12)-0.33%
Revenue beat(16)10
Avg Revenue beat(16)0.07%
PT rev (1m)7.97%
PT rev (3m)17.12%
EPS NQ rev (1m)0.34%
EPS NQ rev (3m)0.62%
EPS NY rev (1m)0.29%
EPS NY rev (3m)6.61%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE 21.91
Fwd PE 18.73
P/S 4.38
P/FCF 58.22
P/OCF 21.03
P/B 9.16
P/tB N/A
EV/EBITDA 14.3
EPS(TTM)0.81
EY4.56%
EPS(NY)0.95
Fwd EY5.34%
FCF(TTM)0.3
FCFY1.72%
OCF(TTM)0.84
OCFY4.76%
SpS4.05
BVpS1.94
TBVpS-2.93
PEG (NY)1.05
PEG (5Y)N/A
Graham Number5.94
Profitability
Industry RankSector Rank
ROA 1.74%
ROE 10.07%
ROCE 11.68%
ROIC 9.23%
ROICexc 10.27%
ROICexgc 21.53%
OM 29.89%
PM (TTM) 4.82%
GM 55.98%
FCFM 7.53%
ROA(3y)-1.47%
ROA(5y)-0.34%
ROE(3y)-14.75%
ROE(5y)-6.62%
ROIC(3y)8.04%
ROIC(5y)7.61%
ROICexc(3y)9.2%
ROICexc(5y)8.42%
ROICexgc(3y)32.15%
ROICexgc(5y)28.54%
ROCE(3y)10.18%
ROCE(5y)9.64%
ROICexgc growth 3Y-8.13%
ROICexgc growth 5Y-2.77%
ROICexc growth 3Y3.93%
ROICexc growth 5Y7.64%
OM growth 3Y-0.64%
OM growth 5Y2.13%
PM growth 3Y-31.23%
PM growth 5YN/A
GM growth 3Y-0.57%
GM growth 5Y1.5%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 4.04
Debt/FCF 25.87
Debt/EBITDA 4.55
Cap/Depr 106.02%
Cap/Sales 13.32%
Interest Coverage 2.06
Cash Conversion 49.11%
Profit Quality 156.3%
Current Ratio 2.38
Quick Ratio 2.16
Altman-Z 1.74
F-Score5
WACC11.12%
ROIC/WACC0.83
Cap/Depr(3y)123.61%
Cap/Depr(5y)95.16%
Cap/Sales(3y)18.31%
Cap/Sales(5y)14.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-7.34%
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y20.93%
EPS Next 2Y16.36%
EPS Next 3Y14.51%
EPS Next 5Y15.65%
Revenue 1Y (TTM)-15.95%
Revenue growth 3Y5.71%
Revenue growth 5Y7.17%
Sales Q2Q%9.05%
Revenue Next Year5.31%
Revenue Next 2Y5.6%
Revenue Next 3Y5.78%
Revenue Next 5Y6.85%
EBIT growth 1Y-6.5%
EBIT growth 3Y5.04%
EBIT growth 5Y9.46%
EBIT Next Year29.61%
EBIT Next 3Y13.68%
EBIT Next 5Y12.3%
FCF growth 1Y122.75%
FCF growth 3Y-36.88%
FCF growth 5Y-13.23%
OCF growth 1Y250.92%
OCF growth 3Y-7.31%
OCF growth 5Y8.51%

SOTERA HEALTH CO / SHC FAQ

What is the fundamental rating for SHC stock?

ChartMill assigns a fundamental rating of 5 / 10 to SHC.


What is the valuation status of SOTERA HEALTH CO (SHC) stock?

ChartMill assigns a valuation rating of 6 / 10 to SOTERA HEALTH CO (SHC). This can be considered as Fairly Valued.


What is the profitability of SHC stock?

SOTERA HEALTH CO (SHC) has a profitability rating of 7 / 10.


How financially healthy is SOTERA HEALTH CO?

The financial health rating of SOTERA HEALTH CO (SHC) is 3 / 10.